Kewaunee Scientific Corporation
KEQU
#9374
Rank
$0.10 B
Marketcap
$37.16
Share price
-3.57%
Change (1 day)
14.16%
Change (1 year)

Kewaunee Scientific Corporation - 10-Q quarterly report FY


Text size:
Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 


FORM 10-Q

 


 

xQuarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended January 31, 2006

 

¨Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from              to            

Commission file number 0-5286

 


KEWAUNEE SCIENTIFIC CORPORATION

(Exact name of registrant as specified in its charter)

 


 

Delaware 38-0715562

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S.Employer

Identification No.)

 

2700 West Front Street Statesville, North Carolina 28677
(Address of principal executive offices) (Zip Code)

(704) 873-7202

(Registrant’s telephone number, including area code)

 


Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes   x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and larger accelerated filer in Rule 12b-2 of the Exchange Act.

Large accelerated filer   ¨    Accelerated filer   ¨    Non-accelerated filer  x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).     Yes   ¨    No  x

As of January 5, 2006, the Registrant had outstanding 2,492,270 shares of Common Stock.

Pages: This report, excluding exhibits, contains 19 pages numbered sequentially from this cover page.

 



Table of Contents

KEWAUNEE SCIENTIFIC CORPORATION

INDEX TO FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED JANUARY 31, 2006

 

      Page Number

PART I.

  

FINANCIAL INFORMATION

  

Item 1.

  

Financial Statements

  
  

Consolidated Statements of Operations - Three months and nine months ended January 31, 2006 and 2005

  3
  

Consolidated Balance Sheets January 31, 2006 and April 30, 2005

  4
  

Consolidated Statements of Cash Flows - Nine months ended January 31, 2006 and 2005

  5
  

Notes to Consolidated Financial Statements

  6

Item 2.

  

Management’s Discussion and Analysis of Financial Condition and Results of Operations

  10
  

Review by Independent Registered Public Accounting Firm

  15
  

Report of Independent Registered Public Accounting Firm

  16

Item 3.

  

Quantitative and Qualitative Disclosures About Market Risk

  17

Item 4.

  

Controls and Procedures

  17

PART II.

  

OTHER INFORMATION

  

Item 6.

  

Exhibits

  18

SIGNATURE

  19

 

2


Table of Contents

Part 1. Financial Information

Item 1. Financial Statements

Kewaunee Scientific Corporation

Consolidated Statements of Operations

(Unaudited)

(in thousands, except per share data)

 

   

Three months ended

January 31

  

Nine months ended

January 31

 
   2006  2005  2006  2005 

Net sales

  $17,724  $15,623  $60,351  $54,276 

Costs of products sold

   15,278   13,586   51,034   45,310 
                 

Gross profit

   2,446   2,037   9,317   8,966 

Operating expenses

   3,079   3,030   8,952   9,336 
                 

Operating earnings (loss)

   (633)  (993)  365   (370)

Other income (expense)

   3   (36)  883   4 

Interest expense

   (112)  (84)  (317)  (254)
                 

Earnings (loss) before income taxes

   (742)  (1,113)  931   (620)

Income tax expense (benefit)

   (268)  (382)  326   (227)
                 

Earnings (loss) before minority interests

   (474)  (731)  605   (393)

Minority interests

   81   11   158   48 
                 

Net earnings (loss)

  $(555) $(742) $447  $(441)
                 

Net earnings (loss) per share

     

Basic

  $(0.22) $(0.30) $0.18  $(0.18)

Diluted

  $(0.22) $(0.30) $0.18  $(0.18)

Weighted average number of common shares outstanding (in thousands)

     

Basic

   2,492   2,492   2,492   2,491 

Diluted

   2,494   2,493   2,493   2,495 

See accompanying notes to consolidated financial statements.

 

3


Table of Contents

Kewaunee Scientific Corporation

Consolidated Balance Sheets

(in thousands)

 

   

January 31

2006

  

April 30

2005

 
   (Unaudited)    

Assets

  

Current assets:

   

Cash and cash equivalents

  $890  $225 

Restricted cash

   381   379 

Receivables, less allowance

   19,103   21,683 

Inventories

   6,539   3,542 

Deferred income taxes

   467   456 

Prepaid income taxes

   —     94 

Prepaid expenses and other current assets

   871   401 
         

Total current assets

   28,251   26,780 

Property, plant and equipment, at cost

   36,538   34,467 

Accumulated depreciation

   (25,377)  (23,737)
         

Net property, plant and equipment

   11,161   10,730 

Prepaid pension cost

   4,861   4,731 

Property held for sale

   —     1,450 

Other

   2,741   2,521 
         

Total other assets

   7,602   8,702 

Total Assets

  $47,014  $46,212 
         

Liabilities and Stockholders' Equity

   

Current liabilities:

   

Short-term borrowings

  $6,244  $3,778 

Current portion of long-term debt

   93   931 

Current obligations under capital leases

   220   111 

Accounts payable

   6,873   8,558 

Employee compensation and amounts withheld

   798   1,113 

Deferred revenue

   969   1,261 

Other accrued expenses

   1,543   647 
         

Total current liabilities

   16,740   16,399 

Obligations under capital leases

   532   307 

Deferred income taxes

   384   391 

Accrued employee benefit plan costs

   2,668   2,524 

Other long-term liabilities

   —     2 

Minority interests

   758   600 
         

Total Liabilities

   21,082   20,223 

Stockholders' equity:

   

Common stock

   6,550   6,550 

Additional paid-in-capital

   143   144 

Retained earnings

   19,954   20,031 

Accumulated other comprehensive income

   72   54 

Common stock in treasury, at cost

   (787)  (790)
         

Total stockholders' equity

   25,932   25,989 
         

Total Liabilities and Stockholders' Equity

  $47,014  $46,212 
         

See accompanying notes to consolidated financial statements.

 

4


Table of Contents

Kewaunee Scientific Corporation

Consolidated Statements of Cash Flows

(Unaudited)

(in thousands)

 

   

Nine months ended

January 31

 
   2006  2005 
Cash flows from operating activities:   

Net earnings (loss)

  $447  $(441)

Adjustments to reconcile net earnings (loss) to net cash used in operating activities:

   

Depreciation

   1,635   1,531 

Provision for bad debts

   64   516 

Increase in deferred income tax expense

   (18)  —   

Gain on sale of property held for sale

   (884)  —   

Decrease (increase) in prepaid income taxes

   94   (86)

Decrease in receivables

   2,516   5,715 

(Increase) decrease in inventories

   (2,997)  332 

Increase (decrease) in prepaid pension cost

   (130)  445 

Increase (decrease) in accounts payable and other current liabilities

   1,197   (3,604)

Decrease (increase) in deferred revenue

   (292)  78 

Other, net

   (538)  1,239 
         

Net cash provided by operating activities

   1,094   5,725 
Cash flows from investing activities:   

Capital expenditures

   (1,633)  (674)

Proceeds from sale of property held for sale

   2,500   —   

Increase in restricted cash

   (2)  (14)
         

Net cash provided by (used in) investing activities

   865   (688)
Cash flows from financing activities:   

Decrease in bank overdraft

   (2,301)  —   

Increase (decrease) in short-term borrowings

   2,466   (3,733)

Payments on long-term debt

   (838)  (838)

Payments on capital leases

   (99)  (9)

Dividends paid

   (524)  (523)

Proceeds from exercise of stock options (including tax benefit)

   2   13 
         

Net cash used in financing activities

   (1,294)  (5,090)
         

Increase (decrease) in cash and cash equivalents

   665   (53)

Cash and cash equivalents, beginning of period

   225   805 
         

Cash and cash equivalents, end of period

  $890  $752 
         

See accompanying notes to consolidated financial statements.

 

5


Table of Contents

Kewaunee Scientific Corporation

Notes to Consolidated Financial Statements

(unaudited)

A. Financial Information

The unaudited interim consolidated financial statements of Kewaunee Scientific Corporation (the “Company” or “Kewaunee”) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “Commission”). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, although the Company believes that the disclosures are adequate to make the information presented not misleading.

These interim consolidated financial statements should be read in conjunction with the financial statements and notes included in the Company’s 2005 Annual Report to Stockholders. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.

The preparation of the financial statements requires management to make certain estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates.

Certain prior period amounts have been reclassified to conform to current classifications. These reclassifications had no impact on the results of operations of the Company.

B. Inventories

Inventories consisted of the following (in thousands):

 

   January 31, 2006  April 30,2005

Finished products

  $2,416  $1,054

Work in process

   982   929

Raw materials

   3,141   1,559
        
  $6,539  $3,542
        

For interim reporting, LIFO inventories are computed based on year-to-date quantities and interim changes in price levels. Changes in quantities and price levels are reflected in the interim financial statements in the period in which they occur.

 

6


Table of Contents

C. Balance Sheet

The Company’s April 30, 2005 consolidated balance sheet as presented herein is derived from audited financial statements, but does not include all disclosures required by generally accepted accounting principles.

D. Comprehensive Income

A reconciliation of net earnings and total comprehensive income for the three months and nine months ended January 31, 2006 and 2005 is as follows (in thousands):

 

   

Three months ended

January 31, 2006

  

Three months ended

January 31, 2005

 

Net earnings (loss)

  $(555) $(742)

Change in fair value of cash flow hedge, net of income tax

   -0-   3 

Change in cumulative foreign currency translation adjustments

   74   (70)
         

Total comprehensive income (loss)

  $(481) $(809)
   

Nine months ended

January 31, 2006

  

Nine months ended

January 31, 2005

 

Net earnings (loss)

  $447  $(441)

Change in fair value of cash flow hedge, net of income tax

   2   10 

Change in cumulative foreign currency translation adjustments

   16   (46)
         

Total comprehensive income (loss)

  $465  $(477)

Statement and Financial Accounting Standards (“SFAS”) No. 133, “Accounting for Derivative Instruments and Hedging Activities,” requires that the Company record derivatives on the balance sheet at fair value and establishes criteria for designation and effectiveness of hedging relationships. The nature of the Company’s business activities involves the management of various financial and market risks, including those related to changes in interest rates. The Company may from time-to-time employ derivative financial instruments, such as interest rate swap contracts, to mitigate or eliminate certain of those risks. The Company does not enter into derivative instruments for speculative purposes. The Company had one interest rate swap agreement outstanding at January 31, 2006 that expires February 28, 2006.

 

7


Table of Contents

For the Company’s foreign subsidiaries, assets and liabilities are translated at exchange rates prevailing on the balance sheet date. Revenues and expenses are translated at weighted average exchange rates prevailing during the period and any resulting translation adjustments are reported separately in shareholders’ equity.

E. Stock Options

The Company accounts for stock options using the intrinsic value method. Under this method no compensation expense is recorded since the exercise price of the stock options is equal to the market price of the underlying stock on the grant date. Had compensation expense for the stock options issued been determined consistent with Financial Accounting Standards Board (“FASB”) Statement No. 123R, “Accounting for Stock-Based Compensation,” net earnings and net earnings per share would have been reduced to the following pro forma amounts (in thousands, except per share data):

 

   

Three months ended

January 31, 2006

  

Three months ended

January 31, 2005

 

Net earnings (loss) as reported

  $(555) $(742)

Pro forma compensation cost

   (3)  (9)
         

Net earnings (loss) pro forma

   (558)  (751)

Net earnings (loss) per share – Basic

   

As reported

  $(0.22) $(0.30)

Pro forma

   (0.22)  (0.30)

Net earnings (loss) per share – Diluted

   

As reported

  $(0.22) $(0.30)

Pro forma

   (0.22)  (0.30)
   

Nine months ended

January 31, 2006

  

Nine months ended

January 31, 2005

 

Net earnings (loss) as reported

  $447  $(441)

Pro forma compensation cost

   (9)  (26)
         

Net earnings pro forma

   438   (467)

Net earnings (loss) per share – Basic

   

As reported

  $0.18  $(0.18)

Pro forma

   0.18   (0.19)

Net earnings (loss) per share – Diluted

   

As reported

  $0.18  $(0.18)

Pro forma

   0.18   (0.19)

 

8


Table of Contents

F. Defined Pension Plans

The Company has non-contributory defined benefit pension plans covering substantially all salaried and hourly employees. Effective April 30, 2005, no further benefits will be earned under the plans and no additional participants will be added to the plans. No contributions were paid to the plans during the nine months ended January 31, 2006, and the Company does not expect any contributions to be paid to the plans during the remainder of the current fiscal year.

Pension expense (income) consisted of the following (in thousands):

 

   

Three months ended

January 31, 2006

  

Three months ended

January 31, 2005

 

Service Cost

  $-0-  $129 

Interest Cost

   201   213 

Expected return on plan assets

   (309)  (251)

Amortization of prior service costs

   -0-   3 

Recognition of net loss

   71   59 
         

Net periodic pension cost (income)

  $(37) $153 
   

Nine months ended

January 31, 2006

  

Nine months ended

January 31, 2005

 

Service Cost

  $-0-  $387 

Interest Cost

   597   639 

Expected return on plan assets

   (929)  (753)

Amortization of prior service costs

   -0-   9 

Recognition of net loss

   202   177 
         

Net periodic pension cost (income)

  $(130) $459 

 

9


Table of Contents

Item 2. Management’s Discussion and Analysis

of Financial Condition and Results of Operations

The Company’s 2005 Annual Report to Stockholders contains management’s discussion and analysis of financial condition and results of operations at and for the year ended April 30, 2005. The following discussion and analysis describes material changes in the Company’s financial condition since April 30, 2005. The analysis of results of operations compares the three months and nine months ended January 31, 2006 with the comparable periods of the prior fiscal year.

Results of Operations

Sales for the three months ended January 31, 2006 were $17,724,000, an increase of 13% over sales of $15,623,000 in the same period last year. Sales for the nine months ended January 31, 2006 were $60,351,000, an increase of 11% over sales of $54,276,000 in the comparable period last year. The order backlog at January 31, 2006 was $35.5 million. This compares to a backlog of $35.2 million at the beginning of the quarter and $41.7 million at January 31, 2005.

The gross profit margin for the three months ended January 31, 2006 was 13.8% of sales, as compared to 13.0% of sales in the comparable quarter of the prior year. The gross profit margin for the nine months ended January 31, 2006 was 15.4%, as compared to 16.5% in the comparable period of the prior year. Gross profit margins for the three and nine months of the current year were unfavorably impacted by an unexpected cost of $230,000 that was incurred during the current quarter when the Company’s installation subcontractor on a large project was unable to complete the installation, forcing the Company to contract with a new subcontractor, and an increase of $205,000 in energy costs during the current quarter over the same period last year.

Operating expenses for the three months ended January 31, 2006 were $3.1 million, or 17.4% of sales, as compared to $3.0 million, or 19.4% of sales, in the comparable period of the prior year. Operating expenses as a percent of sales declined during the current quarter as compared to the comparable quarter of the prior year, as operating expenses were relatively flat in total, while sales increased 13% over the comparable period. In the current quarter, a decrease of $162,000 in bad debt expense from the prior year period substantially offset a $102,000 increase in sales commissions and a $109,000 increase in all other operating expenses. Operating expenses for the nine months ended January 31, 2006 were $9.0 million, or 14.8% of sales, as compared to $9.3 million, or 17.2% of

 

10


Table of Contents

sales, in the comparable period of the prior year. Operating expenses for the nine months ended January 31, 2006 declined by $384,000 as compared to the comparable prior year period, while sales increased 11% over the comparable period. The decline of $384,000 resulted primarily from a $452,000 decline in bad debt expense, partially offset by a $70,000 increase in sales commissions, while other operating expenses were flat.

An operating loss of $633,000 and operating earnings of $365,000 were recorded for the three and nine months ended January 31, 2006, respectively, as compared to operating losses of $993,000 and $370,000 recorded for the comparable periods of the prior year.

Interest expense was $112,000 and $317,000 for the three months and nine months ended January 31, 2006, respectively, compared to $84,000 and $254,000 for the same periods of the prior year. The increase in interest expense for the current year periods resulted from higher interest rates, which was partially offset by lower borrowing levels.

Other income was $3,000 and $883,000 in the three months and nine months ended January 31, 2006, respectively, compared to other expense of $36,000 and other income of $4,000 for the comparable periods of the prior year. Other income for the nine months ended January 31, 2006 included a gain of $884,000 from the sale of the Company’s Lockhart, Texas property in the first quarter.

An income tax credit of $268,000 and income tax expense of $326,000 were recorded for the three months and nine months ended January 31, 2006, respectively, as compared to income tax credits of $382,000 and $227,000 recorded for the comparable periods of the prior year. The effective tax rate was 36.1% and 35.0% for the three and nine months ended January 31, 2006 and was 34.3% and 36.6% for the three months and nine months ended January 31, 2005, respectively. The effective tax rate for each of these periods differs from the statutory rate due to the impact of state and federal tax credits on the different levels of taxable earnings or loss for the periods.

Minority interests result from the Company’s two subsidiaries that are not 100% owned by the Company. Minority interests reduced net earnings by $81,000 and $158,000 for the three and nine months ended January 31, 2006, respectively, as compared to reductions of $11,000 and $48,000 for the comparable periods of the prior year.

 

11


Table of Contents

A net loss of $555,000, or $(0.22) per diluted share, and net earnings of $447,000, or $.18 per diluted share, were recorded for the three and nine months ended January 31, 2006, respectively. This compares to net losses of $742,000, or $.30 per diluted share, and $441,000, or $.18 per diluted share, for the three and nine month periods of the prior year. Net earnings for the nine months ended January 31, 2006 included an after-tax gain of $540,000, or $.22 per diluted share, resulting from the sale of the Company’s former plant site in Lockhart, Texas.

Liquidity and Capital Resources

Historically, the Company’s principal sources of liquidity have been funds generated from operations, supplemented as needed by short-term borrowings under the Company’s revolving credit facility. Additionally, certain machinery and equipment are financed by non-cancelable operating leases or capital leases. The Company believes that these sources will be sufficient to support ongoing business requirements, including capital expenditures through the current fiscal year.

The Company had working capital of $11.5 million at January 31, 2006, as compared to $10.4 million at April 30, 2005. The ratio of current assets to current liabilities was 1.7-to-1 at January 31, 2006, as compared to 1.6-to-1 at April 30, 2005. At January 31, 2006, advances of $6,244,000 were outstanding under the Company’s revolving credit loan, leaving available credit under this line in the amount of $2,756,000.

The Company’s operations provided cash of $1,094,000 during the nine months ended January 31, 2006. Cash was provided primarily from operations, a decrease in accounts receivable, and increases in accounts payable and other current liabilities. The favorable impact of these items was partially offset by cash requirements resulting from an increase in inventories. The increase in inventory levels was primarily the result of (1) inventory of $700,000 for a completed order in transit to an overseas customer and (2) increased inventory levels of certain raw materials purchased from offshore vendors.

The Company’s operations provided cash of $5,725,000 during the nine months ended January 31, 2005, primarily from a significant decrease in accounts receivable resulting from lower sales levels during the period, and cash received from the cancellation of certain life insurance policies. Cash of $3,604,000 was used during this period for the reduction of accounts payable and other current liabilities.

 

12


Table of Contents

During the nine months ended January 31, 2006, net cash of $865,000 was provided by investing activities, primarily $2,500,000 received from the sale of the Company’s former plant site in Lockhart, Texas, reduced by $1,633,000 of capital expenditures. This compares to the use of $688,000 for investing activities in the same period of the prior year, primarily for capital expenditures.

The Company’s financing activities used cash of $1,294,000 during the nine months ended January 31, 2006. Cash used included $2,301,000 to reduce bank overdrafts (reported in the balance sheet as a component of accounts payable), $838,000 for scheduled repayments of long-term debt, and $524,000 for the payment of cash dividends. The impact of these items was partially offset by cash of $2,466,000 provided from advances under the revolving credit loan. Financing activities used cash of $5,090,000 in the same period of the prior year. This included $3,733,000 for repayment of advances under the revolving credit loan, scheduled long-term debt repayments of $838,000, and cash dividends paid of $523,000.

Outlook for Remainder of Fiscal Year 2006

In addition to general economic factors affecting the Company and its markets, demand for the Company’s products is also dependent upon the number of laboratory construction projects planned and/or current progress in projects already under construction. The Company’s ability to predict future demand is very limited given, among other general economic factors affecting the Company and its markets, the Company’s role as subcontractor or supplier to dealers of subcontractors.

 

13


Table of Contents

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Certain statements in this report constitute “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. These factors include, but are not limited to, economic, competitive, governmental, and technological factors affecting the Company’s operations, markets, products, services, and prices. The cautionary statements made pursuant to the Reform Act herein and elsewhere by the Company should not be construed as exhaustive or as any admission regarding the adequacy of disclosures made by the Company prior to the effective date of the Reform Act. The Company cannot always predict what factors would cause actual results to differ materially from those indicated by the forward-looking statements. In addition, readers are urged to consider statements that include the terms “believes”, “belief”, “expects”, “plans”, “objectives”, “anticipates”, “intends” or the like to be uncertain and forward-looking.

 

14


Table of Contents

REVIEW BY INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

A review of the interim financial information included in this Quarterly Report on Form 10-Q for the three months and nine months ended January 31, 2006 has been performed by Cherry, Bekaert & Holland L.L.P., the Company’s independent auditors. Their report on the interim financial information follows.

 

15


Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders of

Kewaunee Scientific Corporation

Statesville, North Carolina

We have reviewed the accompanying consolidated balance sheet of Kewaunee Scientific Corporation and its subsidiaries (the “Company”) as of January 31, 2006, and the related consolidated statements of operations for each of the three-month and nine-month periods ended January 31, 2006, and the consolidated statement of cash flows for the nine-month period ended January 31, 2006. These interim financial statements are the responsibility of the company’s management.

We conducted our review in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States), the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our review, we are not aware of any material modifications that should be made to the consolidated interim financial statements referred to above for them to be in conformity with accounting principles generally accepted in the United States of America.

Cherry, Bekaert & Holland L.L.P.

Charlotte, North Carolina

March 7, 2006

 

16


Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There are no material changes to the disclosures made on this matter in the Company’s Annual Report on Form 10-K for the fiscal year ended April 30, 2005.

Item 4. Controls and Procedures

(a) Evaluation of disclosure controls and procedures

An evaluation was performed under the supervision and the participation of the company’s management, including the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of January 31, 2006. Based on that evaluation, the Company’s management, including the CEO and CFO, concluded that, as of January 31, 2006, the Company’s disclosure controls and procedures were adequate and effective and designed to ensure that all material information required to be filed in this quarterly report is made known to them by others within the Company and its subsidiaries.

(b) Changes in internal controls

There were no significant changes in the Company’s internal controls or in other factors that could significantly affect these controls subsequent to January 31, 2006. As no significant deficiencies or material weaknesses were found, no corrective actions were taken.

 

17


Table of Contents

PART II. OTHER INFORMATION

Item 6. Exhibits and Reports on Form 8-K

 

10.2D Fourth Amendment to the Re-Established Retirement Plan for Hourly Employees
31.1 Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2 Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

18


Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 KEWAUNEE SCIENTIFIC CORPORATION
                      (Registrant)
Date: March 13, 2006 By 

/s/ D. Michael Parker

  D. Michael Parker
  Senior Vice President, Finance and
  Chief Financial Officer

 

19